Purpose: Consider a 2x2x1.5 cm basal cell cancer invading right medial canthus periocular embryonic fusion plane. Usual techniques fail: an irregular PTV 4x4x2.5 cm deep, a concave surface, a deep tumour, and adjacent ocular structures. Oculoplastics/Mohs risk enucleation. Electrons with an internal eye shield require bolus and limit energy to 9 MeV. High energy conformal RT risks medial retinal damage. Systemic agents may palliate but do not cure. We describe low energy electron RT (e-) with an orthovoltage (ortho) bump. "Bump" modulates energy by replacing some e-dose with ortho to increase surface dose and optimize dose distribution. Bump applies to any anatomic location to a depth of 2-3 cm. Bump can use e-with a tungsten eye shield and ortho for maximal eye-sparing. With orbit invaded, morbidity follows. Radiotherapy may be the best eyepreserving option. Methods and Materials: Central-axis dose calculation using measured % depth dose were compared with central and offcentral axis dose calcs using kVDoseCalc, a dose engine validated in kV cone-beam and ortho therapy; and Monte Carlo for e-offaxis dose calc. We compare conformal RT, arcs, and bump, for periocular cancer cases. We compared central axis data for a 4x4 cm field with: 1) 9 MeV alone; 2) 9 MeV with 0.7 cm custom wax; 3) 9 MeV, 80% of dose, 100 kV DXR bump, SSD 10 cm, 20% of dose; 4) 9 MeV, 80% of dose, 200 kV DXR bump, SSD 50 cm, 20% of dose. Patients treated at our institution in 10 or 20 treatments received 8 or 16 electron treatments (prescribed to account for REB of electrons) and 2 or 4 photons treatments, for a total dose of 45 Gy in 10 fractions, or 50 Gy in 20 fractions. Results: For the case above tables based on measured dose give: Surface dose (1) 86%; (2) 90%; (3) 100%; (4) 94% Dmax (100%) (1) 2.0 cm; (2) 1.3 cm; (3) 2.0 cm; (4) 2.0 cm Dose @ 2.7 cm (1) 89%; (2) 58%; (3) 87%; (4) 91% Surface and depth refer to skin surface. Dose is normalized: Dmax = 100%. REB and geometry are not included. Comparing dynamic conformal ARCs, VMAT, electrons +/-bolus or tantalum mesh, and bump show the benefits of 9 MeV with 100-200 kV bump. Dose drop off is swift at ~40%/cm beyond D90%. Dose spares eye. Low SSD, low kV bump results in best homogeneity and surface dose; high kV bump gives best dose at depth. Patients can be scanned with a 3D printer wax replica eye shield to reduce artifact and enable accurate dose calculation. Actual patient results are illustrated with isodose distributions; for three clinical cases, the dose above 80% to retina was 2.5 cc for conformal treatment, 1.0 cc for dynamic conformal arc and < 0.5 cc for bumps, demonstrating excellent shielding for the bump technique. Conclusions: Energy modulation with ortho and electrons can result in improved dose distribution. Benefits include: increased treatment depth, improved dose homogeneity, no bolus, increased shield effectiveness, and reduced penumbra; important when treating near the eye.
Purpose: Chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) represents a novel technique for detecting cell death in vivo, without the need for injected exogenous contrast media or lengthy wait times (as with standard anatomical assessment of tumour response). Changes in CEST signal parameters corresponding to amide, amine, and aliphatic tissues have been suggested to correlate with necrosis. In this study, we sought to characterize the changes in CEST parameters over time to help determine the optimal time point to detect cell death. Methods and Materials: CEST MRI data were acquired from xenografted MDA-231 breast cancer tumours (n = 12) before and after injection with doxorubicin (100 mg/m2) and paclitaxel (50 mg/m2) chemotherapy. Tumours were scanned at baseline and three different treatment times -4, 8, and 12 hours after injection. Acquired data was fitted to Lorentzian shapes using a previously described method. The peak amplitude is measured as a unitless ratio of the measured signal to the CEST signal of bulk water; area under the curve is in units of parts per million (ppm), related to the resonant frequency of measured protons. Baseline CEST parameters were compared to parameters at each treatment time using two-tailed T tests with p-value for significance of ≤ 0.05. Results: For the aliphatic peak, amplitude measured 0.063 ± 0.009 at baseline, 0.066 ± 0.009 at four hours, 0.095 ± 0.013 at 8 hours, and 0.065 ± 0.019 at 12 hours post-injection; only the change from baseline to eight hours was statistically significant (p = 0.02). Significant change in area under the curve (0.051 ± 0.014 to 0.115 ± 0.015 ppm; p = 0.006) was also observed at eight hours post-injection but not at four or 12 hours. For the amine peak, significant changes in amplitude were observed at eight hours (p < 0.001) and 12 hours (p < 0.001) post-injection; amplitude change was not significant at four hours nor was any change in peak area at any time point. For the amide peak, no significant differences were seen from baseline at any time point for peak amplitude or area. Conclusions: Our results suggest that eight hours after injection of chemotherapy may represent the optimal time to measure cell death using CEST MRI, as significant changes were observed in aliphatic and amine peak amplitudes at this time point.
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MEASUREMENT OF TUMOUR HYPOXIA IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) USING POSITRON EMISSION TOMOGRAPHY (PET) WITH 18F-FLUOROAZOMYCIN ARABINOSIDE (18F-FAZA) Angela Lin 1 , Douglaas Vines 2 , Brandon Driscoll 2 , Lisa W. Le 2 , Stephen Breen 2 , Alexander Sun 2 1 Princess Margaret Cancer Centre, Toronto, ON 2 University of Toronto, Toronto, ON Purpose: Tumour hypoxia is an adverse prognostic factor in many cancers. 18F-FAZA is a hypoxia tracer, which can provide a noninvasive method of hypoxia imaging with PET, but has not been widely studied in NSCLC. This study aims to evaluate the feasibility and potential benefits of using 18F-FAZA-PET scans to assess NSCLC tumour hypoxia. Methods and Materials: Thirteen of the planned 20 patients with Stage II -III NSCLC are included thus far in this prospective study by imaging with FAZA-PET before initiation of radical chemoradiotherapy. Patients were imaged two hours post-injection with FAZA. Attenuation correction was performed using a helical computed tomography (hCT) for respiratory gated PET (gPET). The exhale bin was used for analysis for the purpose of this study. The hypoxic volume (HV) was defined as all voxels within the tumour with standard uptake value (SUV) more than three standard deviations from the mean values obtained from muscle SUV as defined by Mortensen et al. 2012. The Tmax/Mmean ratio was defined as maximum tumour SUV divided by the mean erector spinae muscle SUV. The hypoxic fraction (HF) was determined by dividing the HV by the entire gross tumour volume (GTV). Pearson correlation (rho) was performed to evaluate whether some of these metrics are correlated. Results: A hypoxic volume (HV) in the primary tumour was identified in 12 patients (92.3%). The hypoxic fraction (HF) S62 CARO 2016 _________________________________________________________________________________________________________ varied from 0 to 46.8% (median 4.2%) in the primary tumour. The Tmax/Mmean ranged from 1.37 to 4.23 (median 1.98). There was no correlation between lesion size and SUVmax or between lesion size and HF, which suggests that larger tumours are not necessarily more hypoxic than smaller tumours. A significant correlation between Tmax/Mmean and HF was observed (rho = 0.83, p < 0.001), and between SUVmax and HF (rho = 0.74, p = 0.004). This may suggest that tumours with a higher SUVmax (ie. higher intensity of hypoxia) also have a larger proportional volume of hypoxia. Conclusions: 18F-FAZA PET scans provide a feasible non-invasive method to assess NSCLC tumour hypoxia. A hypoxic volume, as detected by 18F-FAZA PET, was present in the majority of NSCLC patients in our study. Ongoing trial accrual and follow up of our patient cohort will provide more information with regards to the imaging and clinical value of 18F-FAZA PET, and we hope to correlate these imaging metrics with clinical outcomes.
DEVELOPMENT OF PROVINCIAL PALLIATIVE RADIOTHERAPY GUIDELINES
Derek Tilley 1 , Marc Kerba 2 , Xanthoula Kostaras 1 , Alysa Fairchild 3 , 1 Alberta Health Services, Calgary, AB 2 University of Calgary, Calgary, AB 3 University of Alberta, Edmonton, AB Purpose: Radiotherapy (RT) practice variability in the palliative setting is well-documented. Clinical practice guidelines inform standardized, evidence-based, beneficial practice, while simultaneously discouraging unnecessary or potentially harmful practices. The process of creating provincial palliative RT clinical practice guidelines is associated with multiple challenges. We describe the unique approach required in aligning multidisciplinary goals as compared to traditional tumour sitespecific guidelines. Methods and Materials: Radiation oncologists from the provincial Palliative Care Tumour Team, along with guideline specialists from the Guideline Resource Unit, formed the primary guideline working group tasked with updating the Palliative RT guidelines. Tumour site specific representatives (ex. Central Nervous System Tumour Team) were incorporated as needed, as well as experts in supportive care, on a guideline by guideline basis. For each guideline, a systematic literature review was conducted to identify relevant evidence. Recommendations were initially developed within the primary working group, then revised in collaboration with experts from other disciplines. Once working group consensus was reached, guideline recommendations were circulated to all radiation oncologists and Palliative Tumour Team members for input. After several rounds of feedback and modifications, provincial consensus was reached. Results: Initially, one RT guideline had been created for all provincial palliative RT recommendations. These guidelines have since been split into smaller, more functional palliative RT guidelines: 1) Brain Metastases; 2) Bone Metastases and Spinal Cord Compression; 3) Bleeding and Gastrointestinal Obstruction; and 4) Superior Vena Cava Obstruction, Dyspnea, and Hemoptysis. The majority of recommendations were either modified or new due to advancements in research or changes in consensus based approaches. In total, 70 recommendations were approved. Recommendations were supported by a range of evidence from high (level one evidence) to low quality (consensus opinion). Conclusions: By combining the newly updated palliative RT guidelines with an educational intervention, variations in practice may be mitigated. Using our model, similar efforts can be undertaken in other jurisdictions.
SYSTEMATIC REVIEW OF PATIENT REPORTED QUALITY OF LIFE FOLLOWING STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PRIMARY AND METASTATIC LIVER CANCER Adam Mutsaers, Jeffrey Greenspoon, Cindy Walker-Dilks, Anand Swaminath
McMaster University, Hamilton, ON Purpose: Stereotactic ablative body radiotherapy (SABR) is an emerging modality in patients with liver cancer who are ineligible for other local therapies. It has been shown to be effective with respect to long-term tumour control with minimal toxicity. However SABR for liver cancer is not current standard of practice despite its potential promise. In order to validate increased offering of this promising therapy, objective systematic data regarding impact on quality of life (QOL) is required. No systematic reviews to date have been performed to analyze QOL for primary or metastatic liver cancers. QOL metrics are a critical part of therapy evaluation, particularly in disease states with short life expectancy. The purpose of this study was to conduct a systematic review of evidence surrounding QOL for liver SABR. Methods and Materials: MEDLINE and EMBASE databases from 1996 to October 2015 were queried to obtain English language studies analysing QOL following SABR for liver cancers. Included studies involved patient-reported QOL as either a primary or secondary endpoint, along with analysis of QOL change over time. Studies were screened by three reviewers, while relevant data were abstracted and analyzed by a single reviewer. Results: Of 2181 initially screened studies, five met all inclusion criteria and were analyzed. Extracted study dates ranged from 2008 to 2015, included a total of 388 eligible patients, and 4/5 studies were prospective in design. All were published studies, with the exception of one conference abstract. Studies included patients with hepatocellular carcinoma, liver metastases and intrahepatic cholangiocarcinoma. Extracted studies were heterogeneous in dose prescription used (11-70 Gy in 3 -30 fractions), as well as in QOL metrics (EORTC QLQ C-15 PAL,/C-30/LM-21, Euroqol 5D, FACT-Hep, FLIC) and final endpoints (range: six weeks to 12 months). Despite this there were few clinically or statistically significant declines in QOL scores following SABR. Four studies demonstrated increased fatigue transiently in the first 1-4 weeks, while two studies showed transient worsening of appetite at one month; both metrics returned to insignificant difference from baseline by the final endpoints. All studies showed no significant decline in QOL at their respective endpoints. In studies with overlapping QOL tools, estimates of three-month post-SABR global QOL were similar. Conclusions: Results of this systematic review demonstrate wellpreserved post SABR QOL in patients with otherwise untreatable liver cancer, despite heterogeneity amongst the individual studies themselves. These findings merit further research to increase data collection, to validate QOL tools specific to SABR for liver cancers, and to support comparative effectiveness trials of SABR with other local modalities in liver cancer including surgery, chemoembolization and radiofrequency ablation, with a focus on QOL outcomes as an important endpoint.
